news
Innovative vaccine demonstrates sustained malaria immunisation in pregnancy
Follow up research to the presented findings could provide improved opportunities for preventing malaria in women during pregnancy.
List view / Grid view
Malaria
news
Key vaccine adjuvant biosynthesised
UK scientists have unlocked the potential of bioengineering vaccine adjuvants, based on a study of the molecule QS-21.
news
WHO recommends second malaria vaccine
Newly recommended by the World Health Organization (WHO), the new “safe, effective and affordable” malaria vaccine has potential to reduce deaths "by up to a third”.
news
CPHI Pharma Awards 2023 finalists announced
The finalists for CPHI’s Pharma Awards 2023 across twelve categories for innovation, manufacturing, sustainability, best start-up initiative and breakthrough digital technologies have been announced.
news
Pioneering malaria vaccine gains regulatory clearance
University of Oxford-developed R21/Matrix-M malaria vaccine has secured approval in two African countries.
news
CHMP meeting highlights – January 2023
Four new medicines were recommended for approval at the Committee for Medicinal Products for Human Use (CHMP)’s January meeting, with positive opinions given to two type 2 diabetes drugs.
news
Monoclonal antibody could prevent malaria, study shows
Based on recent research, a "potential game changer” approach could offer a practical way to use monoclonal antibody therapies for malaria in Africa.
news
UNICEF signs first ever malaria vaccine supply contract with GSK
Securing 18 million doses of GSK’s RTS,S malaria vaccine, UNICEF calls the contract a major breakthrough for child health.
article
Tackling the silent pandemic: AMR Industry Alliance sets the Standard
Here AMR Industry Alliance representatives Melissa Gong Mitchell and Steve Brooks discuss how the Alliance is mobilising the life sciences sector in combatting antimicrobial resistance (AMR). They present the newly established antibiotics manufacturing standard that aims to minimise pharma’s contribution to AMR in the environment, considering the critical considerations and…
news
L9LS antibody safe and highly protective against malaria, finds study
Phase I human challenge study shows a single subcutaneous injection of the monoclonal antibody L9LS provides at least short-term protection against malaria.
news
Afrigen to collaborate with NIAID on mRNA vaccine research
The research collaboration will enable the sharing of technical skills and materials to expedite Afrigen’s goal of mRNA vaccine production.
![Sanofi logo on top of building [Credit: HJBC/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Sanofi-1-300x278.jpg)
![Sanofi logo on top of building [Credit: HJBC/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Sanofi-1.jpg)
news
Sanofi launches Impact® brand of medicines for low-income countries
Sanofi Global Health — a nonprofit unit of Sanofi set up in 2021 — has launched Impact®, a new brand of standard of care medicines dedicated for nonprofit distribution in 40 of the world’s lower-income countries.
news
Healthier Together and philanthropic ventures in tropical disease
Europe launches the EU Non-communicable diseases (NCDs) initiative, while GSK and Novartis promise millions to support drug R&D for neglected tropical diseases and malaria.
news
BioNTech launches African vaccine production in Rwanda
Marking the initiation of its African vaccine manufacturing network, BioNTech begins construction of its hub site in Rwanda.
![Roche logo sign lit up [Credit: testing/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Roche-3-300x278.jpg)
![Roche logo sign lit up [Credit: testing/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Roche-3-e1652444508201.jpg)
news
Roche announces plans to improve diagnosis and treatments in developing countries
Roche shares initiative commitments that will extend prophylactic treatment access to patients with haemophilia, as well as investments to provide testing capabilities for HIV and Tuberculosis in developing countries.
